Equities research analysts at StockNews.com started coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
Calithera Biosciences Price Performance
Shares of Calithera Biosciences stock opened at $0.05 on Friday. Calithera Biosciences has a 1 year low of $0.05 and a 1 year high of $13.38. The business has a 50-day moving average of $0.22 and a two-hundred day moving average of $1.82. The company has a market capitalization of $243,500.00, a P/E ratio of 0.00 and a beta of 1.22.
Insider Buying and Selling
In related news, Director Deepika Pakianathan sold 121,333 shares of the stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $0.39, for a total transaction of $47,319.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.60% of the stock is owned by corporate insiders.
Institutional Trading of Calithera Biosciences
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.